|
Partnering
Opportunities
Fabre-Kramer places a strong emphasis on partnering activities.
As a virtual company, everything we do involves collaboration
with third parties.
In Licensing
Fabre-Kramer does not engage in drug discovery activities. Therefore,
all of its portfolio compounds are the result of its in-licensing
activities. We have completed eight (8) such licensing transactions
to date, and have acquired intellectual property and assets from
major pharmaceutical companies, small developing pharmaceutical
companies, academic and medical institutions, and individual inventors/discoverers.
As a privately-held company, Fabre-Kramer is able to make decisions
quickly on opportunities it finds to be a fit with its therapy
focus and business objectives. In general, we seek products that
have been in at least Phase I or Phase II clinical trials, are
intended to treat large populations of patients in one or more
psychiatric or neurological indications. We have occasionally
in-licensed pre-clinical compounds that we feel offer unusually
attractive opportunities.
Development
Fabre-Kramer’s expertise is concentrated around clinical
development of psychotropic compounds. Its principals and advisors
are world-renowned clinical investigators of this class of drugs
and have designed and conducted many pivotal trials and contributed
numerous additions to the knowledge base in the field. We leverage
this expertise to increase the odds of success in development
programs we develop and manage for compounds we have acquired.
We have relationships with highly regarded investigators all over
the world and closely monitor and oversee the CROs that we use
to conduct our studies. We have expert consultants in all relevant
fields of development including intellectual property, manufacturing,
regulatory, legal, and other areas to assist in our development
programs. We are consistently able to develop compounds faster,
cheaper and more effectively than other companies using this approach.
Out Licensing
At present, Fabre-Kramer has no desire to develop its own marketing
capabilities. We seek to partner our portfolio compounds with
third parties who can provide the people and financial resources
to optimize our compounds market potential. Every product we in-license
to develop we believe has the potential to generate in excess
of $1 billion in peak year annual sales. These products require
significant resources to bring to market effectively. We strive
to develop our compounds to the early to mid Phase III level,
in most cases, and then begin to seek partners to fund the remaining
Phase III and IV clinical activities and to market the product
upon FDA or other regulatory authority approval. We seek to negotiate
terms with our partners that are consistent with industry norms
for compounds at this stage of development with similar commercial
potential. Fabre-Kramer can be very flexible in terms of the structure
of its licensing transactions, and, as is the case in our in-licensing
activities, can move very quickly to consummate transactions.
Alliances
Axon
Biochemicals, B. V.
Bristol-Myers
Squibb Company
Ferrer
grupo
GlaxoSmithKline
Pfizer
Schering-Plough
University
of Strathclyde
|
